For infectious disease studies of any kind, the ability to accelerate trial timelines, while also providing high-quality data and reducing barriers to patient participation, is highly prized. And when the World Health Organization (WHO) declares a virus a pandemic, there’s no time to lose. Infectious disease drug developers must respond immediately to find treatment and prophylactic candidates and rapidly move them through the drug development process.

An Interview With Cogstate Neuropsychologist Robert McCue

CNS clinical outcome assessment — particularly performance-based outcome measures — are among the most complex and nuanced assessments in clinical trials. This complexity's potential impact on data quality and signal detection invites the innovative use of technology to streamline test administration and scoring, such as the use of advanced eCOA ecosystems paired with expert clinical scientific guidance to design workflows. This teamwork enables dramatic improvements in assessment data collection. The ultimate goals are more confident decision-making, more conclusive research, and faster delivery of new medicines to the patients who need them.